Pfizer $PFE+0.8% reported results today. You could say that the results beat expectations, but the revenue just missed expectations. Revenue was down from Q1 this year as sales of the Covid-19 vaccine fell 83% and revenue from the Paxlovide antiviral treatment fell 98%.
I've been buying $PFE+0.8% shares recently as they are currently at a really low price.
Somehow I'm not attracted to this company, so I'm not including